Analysis of influencing factors and interaction of body weight and disease outcome in patients with prediabetes

Table 2 Univariate analysis of the outcome of prediabetes disease

Data	DP group (n = 66)	DO group (n = 170)	t/χ2/Z	P value
Gender			0.143	0.705
Male	39 (59.09)	105 (61.76)
Female	27 (40.91)	65 (38.24)
Age			< 0.001	0.988
< 60 yr	42 (63.64)	108 (63.53)
≥ 60 yr	24 (36.36)	62 (36.47)
Blood glucose status			14.639	0.001
IFG	16 (24.24)	82 (48.24)
IGT	28 (42.42)	62 (36.47)
IFG and IGT coexistent	22 (33.33)	26 (15.29)
Family history of diabetes			0.279	0.598
Yes	6 (9.09)	12 (7.06)
No	60 (90.91)	158 (92.94)
Smoking history			4.561	0.033
Yes	20 (30.30)	30 (17.65)
No	46 (69.70)	140 (82.35)
Drinking history			5.457	0.019
Yes	26 (39.39)	41 (24.12)
No	40 (60.61)	129 (75.88)
Weight, kg (mean ± SD)	74.59 ± 11.19	66.91 ± 11.86	4.535	< 0.001
Waist circumference, cm (mean ± SD)	106.84 ± 10.31	101.98 ± 10.95	3.110	0.002
BMI, kg/m2 (mean ± SD)	32.37 ± 3.58	30.41 ± 3.75	0.074	0.941
FBG, mmol/L (mean ± SD)	5.98 ± 0.73	6.08 ± 0.75	0.926	0.355
2h PG, mmol/L (mean ± SD)	8.12 ± 1.83	7.54 ± 1.84	2.177	0.031
Systolic blood pressure (mmHg)	128 ± 21	122 ± 20	2.040	0.043
Diastolic blood pressure (mmHg)	81 ± 11	80 ± 10	0.670	0.503
Glycosylated hemoglobin (%)	6.28 ± 0.53	5.89 ± 0.33	6.794	< 0.001
TC (mmol/L)	4.76 ± 1.17	4.64 ± 1.06	0.758	0.449
TG (mmol/L)	1.58 ± 0.32	1.42 ± 0.47	2.544	0.012
HDL-C (mmol/L)	1.25 ± 0.27	1.21 ± 0.32	0.899	0.370
LDL-C (mmol/L)	1.88 ± 0.53	1.85 ± 0.41	0.463	0.644
Uric acid (μmol/L)	3.43 ± 0.76	3.20 ± 0.87	2.067	0.040
SLA (μmol/L)	325.10 ± 75.04	300.22 ± 80.23	2.176	0.031
FINS (μU/mL)	5.96 ± 1.57	5.11 ± 1.19	6.016	< 0.001
HOMA-IR	1.67 ± 0.45	1.21 ± 0.39	7.782	< 0.001

Results presented as n (%), unless indicated otherwise. DP: Disease progression; DO: Disease outcome; IFG: Impaired fasting glucose; IGT: Impaired glucose tolerance; BMI: Body mass index; FBG: Fasting blood glucose; 2h PG: 2h postprandial blood glucose; TC: Total cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; SLA: Anti-soluble liver antigen antibodies; FINS: Fasting insulin; HOMA-IR: Homeostatic model assessment for insulin resistance.